Sage Therapeutics will report the first pivotal data with its oral postpartum depression candidate, while Biohaven Pharma transfers its hopes to a faster-acting migraine…
The amyloid hypothesis of Alzheimer's has taken another battering – and some companies are finally taking a new approach.
Biohaven might soon be going up against Allergan in the acute migraine space, but the company believes size will not be a barrier to its success.
Another billion dollar quarter for biotech IPOs signals that investor appetite for high-risk offerings is strong.
The biotech IPO market records its first billion dollar quarter in two years as demand for new issues recovers.